JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB120068

Mirtazapine, alpha2, 5-HT2, 5-HT3 antagonist

Be the first to review this product! Submit a review

|

(3 Publications)

MW 265.35 Da, Purity >99%. Antagonist at α2, 5-HT2 and 5-HT3 receptors. Antidepressant *in vivo*. Achieve your results faster with highly validated, pure and trusted compounds.
1 Images
Chemical Structure - Mirtazapine, alpha2, 5-HT2, 5-HT3 antagonist (AB120068)
  • Chemical Structure

Lab

Chemical Structure - Mirtazapine, alpha2, 5-HT2, 5-HT3 antagonist (AB120068)

2D chemical structure image of ab120068, Mirtazapine, alpha2, 5-HT2, 5-HT3 antagonist

Key facts

CAS number

85650-52-8

Purity

>99%

Form

Solid

form

Molecular weight

265.35 Da

Molecular formula

C<sub>1</sub><sub>7</sub>H<sub>1</sub><sub>9</sub>N<sub>3</sub>

PubChem

4205

Nature

Synthetic

Solubility

Soluble in DMSO to 20 mM

Soluble in ethanol to 50 mM

Biochemical name

Mirtazapine

Biological description

Antagonist at α2, 5-HT2 and 5-HT3 receptors. Antidepressant *in vivo*.

Canonical smiles

CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4

InChi

InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3

InChiKey

RONZAEMNMFQXRA-UHFFFAOYSA-N

IUPAC Name

5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The ADRA2B also known as the alpha 2a and alpha 2C adrenergic receptors is a part of the adrenergic receptor group. This receptor is significant for its role in modulating neurotransmitter release binding norepinephrine and playing a role in various cellular responses. It is a G-protein-coupled receptor with an approximate mass ranging from 50-70 kDa. You find ADRA2B highly expressed in the central and peripheral nervous systems vascular tissues and also in the pancreas. This receptor is sometimes considered alongside the serotonergic receptors like the 5-HT2A 5-HT2C and 5-HT3 important for multiple physiological processes.
Biological function summary

The ADRA2B receptor contributes to the inhibition of adenylate cyclase activity leading to reduced levels of cAMP within cells. It does not function alone; rather it can interact with other G-protein subunits for its regulatory actions. Besides neurotransmission reduced sympathetic outflow and smooth muscle contraction are actions associated with these adrenergic receptors. The involvement of 5-HT receptors like 5-HT2A and 5-HT3A in contrast adds another layer of modulation affecting mood cognition and nausea.

Pathways

ADRA2B and related receptors are key elements within the adrenergic signaling pathway and play roles in the serotonergic signaling pathway. These pathways regulate vital processes like signal transduction chronic pain and cardiovascular functions. Related proteins include G-proteins beta adrenergic receptors and the serotonin receptor subtypes which together mediate an array of physiological functions. Alpha 2 antagonists like mirtazapine influence these pathways by modulating receptor activity and affecting therapeutic outcomes.

ADRA2B and its associated receptors are importantly linked to cardiovascular diseases and certain psychiatric disorders. For instance dysfunctions in adrenergic signaling can contribute to hypertension or heart failure. In psychiatric contexts the imbalance in serotonergic and noradrenergic systems might relate to depression. Drugs such as mirtazapine work by acting as an alpha 2 antagonist helping ameliorate symptoms by modifying receptor interactions therefore showcasing the relevance of these proteins in therapeutic settings.

Product protocols

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Experimental neurology 353:114056 PubMed35358499

2022

Mirtazapine treatment in a young female mouse model of Rett syndrome identifies time windows for the rescue of early phenotypes.

Applications

Unspecified application

Species

Unspecified reactive species

Javier Flores Gutiérrez,Giulia Natali,Jacopo Giorgi,Elvira De Leonibus,Enrico Tongiorgi

Journal of neurodevelopmental disorders 12:26 PubMed32988385

2020

Protective role of mirtazapine in adult female Mecp2 mice and patients with Rett syndrome.

Applications

Unspecified application

Species

Unspecified reactive species

Javier Flores Gutiérrez,Claudio De Felice,Giulia Natali,Silvia Leoncini,Cinzia Signorini,Joussef Hayek,Enrico Tongiorgi

Scientific reports 10:2491 PubMed32051524

2020

In vitro modeling of dendritic atrophy in Rett syndrome: determinants for phenotypic drug screening in neurodevelopmental disorders.

Applications

Unspecified application

Species

Unspecified reactive species

Elisa Nerli,Ottavia Maria Roggero,Gabriele Baj,Enrico Tongiorgi
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com